Videos

Focusing on immunotherapy management for metastatic bladder cancer, Dr Shah shares notable toxicities, relevant real-world data, and emergent data on maintenance therapy.

Dr Jain discusses latest data in frontline and maintenance therapy for metastatic bladder cancer and Mr. Ehas shares his experiences during the course of his treatment.

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

The panel reviews treatment approaches for graft-versus-host disease when steroids are not an option and explains how the heterogeneity of GVHD makes finding the right treatment challenging.

Closing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Key opinion leaders highlight the variable symptoms of chronic graft-versus-host disease and the importance of educating patients and community physicians to recognize and address early signs.

Expert perspectives on novel treatment strategies in the second-line treatment setting of advanced bladder cancer.

Mr. Ehas shares his initial treatment experience and response to chemo, while Anand Shah, PharmD, BCOP describes an oncology pharmacists’ role in patient education and adverse event management.

Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.

Experts discuss the challenges of grading chronic graft-versus-host disease using NIH criteria, noting the importance of a common language, and considering patient symptoms, performance status, and organ involvement in assessing severity.

Nelson Chao, MD, MBA, presents the clinical scenario of a 53-year-old man with chronic graft-versus-host disease and highlights the complexities of distinguishing between symptoms of acute and chronic GVHD.

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.

Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.

Shared patient perspectives and conversation centered around collaboration in clinical care for metastatic bladder cancer, including the oncology pharmacists’ role in treatment decisions.

Rohit Jain, MD, MPH provides an overview of metastatic bladder cancer, discussing differences in urothelial carcinoma based on location, patient presentations, diagnosis, and staging.

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.